Mercer Health & Benefits, LLC. Mercer's 2005 National Survey of Employer Sponsored Health Plans.New York, NY: 2005.
2.
AldanaS. Financial impact of health promotion programs: a comprehensive review of literature. Am J Health Promot.2001;15:296–320.
3.
AldanaSGMerrillRMPriceK. Financial impact of a comprehensive multisite workplace health promotion program. Prev Med.2004;40:131–137.
4.
AndersonDSerxnerSGoldDB. Conceptual framework, critical questions, and practical challenges in conducting research on the financial impact of worksite health promotion. Am J Health Promot.2001;15:281–286.
5.
ChapmanL. Meta-evaluation of worksite health promotion economic return studies: 2005 update. Am J Health Promot.2005;4:1–11.
EddingtonD. Emerging research: a view from one research center. Am J Health Promot.2001;15:341–349.
8.
FitznerKSiderovJFetterolfD. Principles for Assessing Disease Management Outcomes.Washington, DC: The Disease Management Association of America; In press.
9.
GoetzelRZOzminkowskiRJVillagraVGDuffyJ. Return on investment in disease management: a review. Health Care Financing Rev.2005;Summer:1–19.
10.
GolaszewskiT. Shining lights: studies that have most influenced the understanding of health promotion's financial impact. Am J Health Promot.2001;15:332–340.
11.
HarrisJHarrisJRSchaufflerHH. Expanding health insurance coverage for smoking cessation treatments: experience of the Pacific Business Group on health. Am J Health Promot.2001;15:341–349.
12.
HarveyWWhitmerRWHilyerJCBrownKC. The impact of a comprehensive medical benefit cost management program for the city of Birmingham. Am J Health Promot.1993;7:296–304.
13.
HuntingtonIConnellFA. For every dollar spent: the cost savings argument for prenatal care. N Engl J Med.1994;331:1303–1307.
14.
IssacF. Johnson and Johnson Live for Life Program: now and then. Am J Health Promot.2001;15:365–367.
15.
KrauseD. Economic effectiveness of disease management programs: a meta-analysis. Dis Manag.2005;8:114–134.
16.
KrumholzHMAmatrudaJSmithGL. Randomized trial of an education and support intervention to prevent readmission of patients with heart failure. J Am Coll Cardiol.2002;39:83–89.
17.
OrleansCBarkerDCKaufmanNJ. Helping pregnant smokers quit: meeting the challenge for the next decade. Tob Control.2000;9:ii6–ii11.
18.
OzminkowskiRDunnRLGoetzelRZ. A return on investment evaluation of the Citibank, N.A., Health Management Program. Am J Health Promot.1999;14:31–43.
19.
PelletierKR. A review and analysis of the health and cost-effective outcome studies of comprehensive health promotion and disease prevention programs at the worksite: update VI 2000–2004. J Occup Environ Med.2005;47:1051–1058.
20.
PowellD. Characteristics of successful wellness programs. Empl Benefits J.2000;24:15–20.
21.
SerxnerSGoldDBGrossmeierJAndersonD. The relationship between health promotion program participation and medical costs: a dose response. J Occup Environ Med.2003;45:1196–1200.
SidorovJShullRTomcavageJ. Does diabetes disease management save money and improve outcomes?Diabetes Care.2002;25:684–689.
25.
VillagraVGAhmedT. Effectiveness of a disease management program for patients with diabetes. Health Aff (Millwood).2004;25:255–266.
26.
Congressional Budget Office. An Analysis of the Literature on Disease Management Programs.Washington, DC, 2004.
27.
American Healthways & John's Hopkins, Standard outcomes metrics and evaluation methodology for disease management programs. 2nd Annual Disease Management Outcomes Summit. Palm Desert, Calif, 2002.
28.
AndersonDWhitmerRGoetzelR. The relationship between modifiable health risks and group-level health care expenditures. Am J Health Promot.2000;15:45–52.
29.
LindenAAdamsJRobertsN. Using propensity scores to construct comparable control groups for disease management program evaluation. Dis Manage Health Outcomes.2005;13:107–127.
30.
Guiding Principles for Monte Carlo Analysis.Washington, DC: US Environmental Protection Agency, Risk Assessment Forum; 1997. EPA/630/R-97/001.
